TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03589131

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Baseline demographics
Description: These include gender, age, ASA and BMI. All these data are analyzed and compared in both groups

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative data
Description: These include distance of the tumor from the anal verge, clinical stage, whether preoperative chemoradiation CRT, presence of residual tumor after CRT. All were analyzed and compared
Study: NCT04423432

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Exercise Plan
Description: 2 sets of 10 repetitions/day of~1. AROM isolated knee extension and knee flexion~2. Isometric isolated knee extension and knee flexion~3. Isometric terminal knee extension~4. Sit to stand squat~terminal extension as Home Exercise Program (HEP). (Iwamoto J et al, 2007)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electrotherapy + Heating
Description: Iinterferential Current therapy (2P), in combination with heating pad for 20 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrotherapy + Heating
Description: Iinterferential Current therapy (2P), in combination with heating pad for 20 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrotherapy + Heating
Description: Iinterferential Current therapy (2P), in combination with heating pad for 20 minutes

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Joint Mobilization
Description: 1. Tibio-femoral Anterior Glide~2. Tibio-femoral Posterior Glide~3. Patellofemoral Joint Mobilization

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Joint Mobilization
Description: 1. Tibio-femoral Anterior Glide~2. Tibio-femoral Posterior Glide~3. Patellofemoral Joint Mobilization

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Joint Mobilization
Description: 1. Tibio-femoral Anterior Glide~2. Tibio-femoral Posterior Glide~3. Patellofemoral Joint Mobilization

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine Supplementation
Description: Creatine Supplementation 20g/day for 1 week followed by 5 g/day for 3 weeks
Study: NCT03589131

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative data
Description: These include distance of the tumor from the anal verge, clinical stage, whether preoperative chemoradiation CRT, presence of residual tumor after CRT. All were analyzed and compared
Study: NCT04423432

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucoseamine/ Chondritin Sulfate Supplementation
Description: Glucoseamine/ Chondritin Sulfate Supplementation (500mg+400mg/day)
Study: NCT03683979

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpretation Bias Modification
Description: A computer based interpretation bias modification program that aims to reinforce neutral interpretations of ambiguous social situations.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control Training Program
Description: A sham training program that is similar in design and delivery to the experimental training condition.
Study: NCT03122184

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Psychology + Motivational Interviewing
Description: For the positive psychology portion of the intervention, the study trainer will (a) review the week's positive psychology exercise, (b) discuss the rationale of the next week's positive psychology exercise through a guided review of the positive psychology manual, and (c) assign the next week's positive psychology exercise. For the motivational interviewing portion, participants will (a) review their physical activity goal from the prior week, (b) discuss techniques for improving physical activity, and (c) set a physical activity goal for the next week. Study trainers will use motivational interviewing techniques to facilitate goal setting.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interviewing Health Education
Description: Each week, participants will learn about a different health behavior topic related to cardiac health. They will also be introduced to motivational interviewing topics in concert with the health behavior education topics. The intervention is divided into five sections, focusing on five different important cardiac health-related topics (recovery from an acute cardiac illness, physical activity, a heart-healthy diet, medication adherence, and stress reduction).
Study: NCT03589131

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative data
Description: These include pathological stage, number of harvested lymph nodes and immediate postoperative outcome within one month (days of return of bowel function, days of hospital stay, complications, if any, like anastomotic leakage, ileus,wound problems and others, rate of reoperation, rate of readmission \& 30-days mortality. All were analyzed and compared

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative data
Description: These include pathological stage, number of harvested lymph nodes and immediate postoperative outcome within one month (days of return of bowel function, days of hospital stay, complications, if any, like anastomotic leakage, ileus,wound problems and others, rate of reoperation, rate of readmission \& 30-days mortality. All were analyzed and compared
Study: NCT00690339

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Style 410 Silicone-Filled Breast Implants
Description: Breast Implant Surgery
Study: NCT04266873

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AffloVest
Description: Form of High Frequency Chest Wall Oscillation mimicking manual techniques on a patients thorax to assist with secretion clearance. Delivered for 30 minutes, twice a day
Study: NCT00690339

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Style 410 Silicone-Filled Breast Implants
Description: Breast Implant Surgery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Style 410 Silicone-Filled Breast Implants
Description: Breast Implant Surgery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Style 410 Silicone-Filled Breast Implants
Description: Breast Implant Surgery
Study: NCT00946777

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systane® Ultra
Description: Systane® Ultra 1-2 drops, 4 times per day for 30 days
Study: NCT04378920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEAF-4L6715
Description: LEAF-4L6715
Study: NCT00333658

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal setting and work feedback group
Description: Goal setting and feedback using WBI
Study: NCT03599453

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo Biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chemokine Modulation Therapy
Description: Undergo chemokine modulation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Given by mouth

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Interferon Alfa-2b
Description: Given intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rintatolimod
Description: Given intravenously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given intravenously
Study: NCT00223795

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Single point cane
Description: Participants with symptomatic knee osteoarthritis will undergo gait evaluation with and without a single point cane.
Study: NCT05181254

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: health dialogue
Description: The visual health assessment formulary is based on detailed questions about food, physical activity, heredity, smoking, alcohol, stress and mental illness and measurements such as BMI, blood pressure and blood fats. Patients fill in a web-based questionnaire resulting in a visual colorful scale showing a risk assessment (Figure 1). The Health Dialogue is a prognostic tool that provides an estimate of the increase in risk with current lifestyle habits. The use has shown improvement of lifestyle habits such as smoking cessation, lower intake of fat and higher physical activity level as well as reduced mortality in a long-term follow-up.
Study: NCT01638039

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Tests
Description: Stool, blood, urine and saliva samples

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Tests
Description: Stool, blood, urine and saliva samples
Study: NCT01230047

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducational course
Description: Psychoeducational course on mindfulness and lifestyle interventions for depression and anxiety
Study: NCT03760627

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Refugees Mindfulness Resiliency Training
Description: The intervention consists of meditation, guided imagery, yoga and exercise, biofeedback; self-expression in words, drawings, and movement; and small group support to demonstrate to participants techniques that they can use to self-manage their own stress and trauma.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Mindfulness Resiliency Training
Description: The intervention consists of meditation, guided imagery, yoga and exercise, biofeedback; self-expression in words, drawings, and movement; and small group support to demonstrate to participants techniques that they can use to self-manage their own stress and trauma.
Study: NCT03201562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aceclidine+tropicamide combination
Description: Ophthalmic Solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aceclidine
Description: Ophthalmic Solution

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Vehicle
Description: Ophthalmic Solution
Study: NCT01470040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: discontinuation of aspirin therapy
Description: discontinuation of aspirin therapy

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: continuation of aspirin therapy
Description: continuation of pre-injury low dose aspirin therapy as per previous medical indication
Study: NCT03567798

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: UPLAT
Description: Carica papaya leaf Extract + Tinospora cardifolia Extract

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04926571

Intervention type: DRUG
Intervention: Dexamethasone Oral
Description: New users of Dexamethasone

Intervention type: DRUG
Intervention: Dexamethasone Oral
Description: New users of Dexamethasone
Study: NCT03704857

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive ultrasonic irrigation
Description: PUI will be performed with Newtron P5 ultrasound (Satelec / Acteon Group, Bordeaux, France), at intensity 9 and with a 25mm (# 0.25, taper 0.00). The protocol of use will be 3 sequences of 20 seconds of ultrasonic activation with 2 ml of sodium hypochlorite 2.5% in each root canal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OHIP-14
Description: Patients will respond a quality of life questionnaire (OHIP-14) on the day of endodontic treatment, on the 7th day and on the 30th day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OHIP-14
Description: Patients will respond a quality of life questionnaire (OHIP-14) on the day of endodontic treatment, on the 7th day and on the 30th day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OHIP-14
Description: Patients will respond a quality of life questionnaire (OHIP-14) on the day of endodontic treatment, on the 7th day and on the 30th day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OHIP-14
Description: Patients will respond a quality of life questionnaire (OHIP-14) on the day of endodontic treatment, on the 7th day and on the 30th day.
Study: NCT02429960

Intervention type: DEVICE
Group type: OTHER
Intervention: Analgesia monitor (PhysioDoloris®)
Description: Comparison of three different analgesia monitoring systems (PhysioDoloris®, SPI® and AlgiScan®).
Study: NCT03865537

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cold snare EMR
Description: Participants will have their large polyp removed without electrocautery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cold snare EMR
Description: Participants will have their large polyp removed without electrocautery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hot snare EMR
Description: Participants will have their large polyp removed with electrocautery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hot snare EMR
Description: Participants will have their large polyp removed with electrocautery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Eleview injection
Description: Participants will have their polyp submucosally injected with Eleview

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Eleview injection
Description: Participants will have their polyp submucosally injected with Eleview
Study: NCT04926571

Intervention type: DRUG
Intervention: Dexamethasone Oral
Description: New users of Dexamethasone
Study: NCT03865537

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Placebo injection
Description: Participants will have their polyp submucosally injected with placebo

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Placebo injection
Description: Participants will have their polyp submucosally injected with placebo
Study: NCT02355158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clonidine hydrochloride topical gel, 0.1%
Study: NCT02429960

Intervention type: DEVICE
Group type: OTHER
Intervention: Analgesia monitor (SPI®)
Description: Comparison of three different analgesia monitoring systems (PhysioDoloris®, SPI® and AlgiScan®).

Intervention type: DEVICE
Group type: OTHER
Intervention: Analgesia monitor (AlgiScan®)
Description: Comparison of three different analgesia monitoring systems (PhysioDoloris®, SPI® and AlgiScan®).

Intervention type: DRUG
Group type: OTHER
Intervention: Remifentanil
Description: Remifentanil will be increased step-by-step from 0.05 mcg/kg/min to 0.2 mcg/kg/min. After ensuring a steady-state period of remifentanil infusion of at least 5 minutes, the standardized painful stimuli will be applied.
Study: NCT02427490

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem-Solving Intervention
Description: The problem-solving approach that will be taught in the problem-solving intervention is based on the ADAPT model, which encourages participants to follow five steps when solving problems: focus on adopting a positive attitude to problem-solving, define the problem and set goals, generate a list of alternative solutions to the problem, predict consequences of the alternative solutions, and try implementing the most promising solution from among the list of alternatives. The problem-solving intervention will be delivered by a trained interventionist in three structured sessions using videoconferencing tools.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unenhanced Monitoring
Description: Study participant completes standardized questionnaires upon study enrollment and at two, four, and eight weeks after study enrollment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Unenhanced Monitoring
Description: Study participant completes standardized questionnaires upon study enrollment and at two, four, and eight weeks after study enrollment.
Study: NCT04461886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPC-12G gel
Description: NPC-12G gel is containing 0.2% Sirolimus
Study: NCT04452279

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iStent or iStent inject implantation with concomitant cataract surgery
Description: Standard phacoemulsification cataract surgery followed by ab interno implantation of either iStent or iStent inject trabecular micro-bypass stent(s). Preoperatively and at specified visits through 3 months postoperative, patients will complete evaluations of their ocular surface disease (specifically OSDI score, hyperemia, corneal/conjunctival staining, and tear break-up time).
Study: NCT02365948

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab Pegol
Description: * Active Substance: Certolizumab Pegol~* Pharmaceutical Form: Prefilled syringes~* Concentration: 200 mg/mL~* Route of Administration: Subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab Pegol
Description: * Active Substance: Certolizumab Pegol~* Pharmaceutical Form: Prefilled syringes~* Concentration: 200 mg/mL~* Route of Administration: Subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab Pegol
Description: * Active Substance: Certolizumab Pegol~* Pharmaceutical Form: Prefilled syringes~* Concentration: 200 mg/mL~* Route of Administration: Subcutaneous injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: * Active Substance: Placebo~* Pharmaceutical Form: Prefilled syringes~* Concentration: 0.9 % Saline~* Route of Administration: Subcutaneous injection
Study: NCT03697876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO-165
Description: PRO-165 Chondroitin sulfate 0.18% / sodium hyaluronate 0.2%, ophthalmic gel. Prepared by Sophia Laboratories, S.A. of C.V., Zapopan, Jalisco, Mexico.
Study: NCT02365948

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: * Active Substance: Placebo~* Pharmaceutical Form: Prefilled syringes~* Concentration: 0.9 % Saline~* Route of Administration: Subcutaneous injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: * Active Substance: Placebo~* Pharmaceutical Form: Prefilled syringes~* Concentration: 0.9 % Saline~* Route of Administration: Subcutaneous injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Active Substance: Placebo~* Pharmaceutical Form: Prefilled syringes~* Concentration: 0.9 % Saline~* Route of Administration: Subcutaneous injection
Study: NCT03697876

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artelac
Description: Artelac® Nightime Gel. 0.2% Carbomer, ophthalmic gel. Made in Germany by: Dr. Gerhard Mann Chem Pharm. Imported and marketed by: Bausch \& Lomb México, S.A. de C.V.
Study: NCT00981630

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live attenuated Japanese encephalitis virus
Description: 0.5 mL,Subcutaneous
Study: NCT01795248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: 1.8 mg liraglutide
Study: NCT00981630

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live attenuated Japanese encephalitis virus
Description: 0.5 mL, Subcutaneous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live attenuated Japanese encephalitis virus
Description: 0.5 mL, Subcutaneous

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: ChimeriVax™ diluent (Placebo)
Description: 0.5 mL, Subcutaneous
Study: NCT01795248

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Liraglutide without the GLP-1 analogue
Study: NCT00321594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: belinostat
Description: Given IV
Study: NCT00861549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phencynonate hydrochloride
Description: 2mg/tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phencynonate hydrochloride
Description: 2mg/tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phencynonate hydrochloride
Description: 2mg/tablet
Study: NCT02738840

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI scan
Description: MRI scan
Study: NCT05780788

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monitoring Tooth Movement
Description: Monitoring Canine Retraction
Study: NCT04013555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Description: Flavored effervescent formulation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Flavored effervescent formulation designed to mimic NAC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tryptophan
Description: Oral slurry form

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tryptophan
Description: Oral slurry form
Study: NCT02707224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DP-R208
Description: Investigational product is prescribed to all of randomized subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DP-R208
Description: Investigational product is prescribed to all of randomized subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil
Description: Investigational product is prescribed to all of randomized subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil
Description: Investigational product is prescribed to all of randomized subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Investigational product is prescribed to all of randomized subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Investigational product is prescribed to all of randomized subjects
Study: NCT04618224

Intervention type: DIAGNOSTIC_TEST
Intervention: DDART Testing
Description: One randomly selected eye is included for each study participant. Participants respond to the DDART near vision test with defined environmental conditions at 40 cm viewing distance. All four parameters (RA, MRS, CPS and ACC) are evaluated.

Intervention type: DIAGNOSTIC_TEST
Intervention: wDDART Testing
Description: One randomly selected eye is included for each study participant. Participants respond to the wDDART near vision test with defined environmental conditions at 40 cm viewing distance. All four parameters (RA, MRS, CPS and ACC) are evaluated.